GLUCAGON
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Sep 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Priority Review
GLUCAGON by Eli Lilly and Company is 12. Approved for severe hypoglycemia in pediatric. First approved in 1998.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Glucagon is a small-molecule injectable hormone that treats severe hypoglycemia by activating hepatic glucagon receptors to stimulate glycogen breakdown and glucose release from the liver. It also functions as a diagnostic aid during radiological examinations. Blood glucose concentrations rise within 10 minutes of injection, reaching peak levels of ~136–138 mg/dL within 26–30 minutes depending on route.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30), signaling a contracting brand team and shift toward lifecycle management and generic defense strategies.
Mechanism of Action
12.1 Mechanism of Action Glucagon increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. Hepatic stores of glycogen are necessary for glucagon to produce an antihypoglycemic effect. Extrahepatic…
Worked on GLUCAGON at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.